Plus Therapeutics rebrands to Cerenome, changes ticker to CNSY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026 8:30 AM EDTHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Companys name will become Cerenome, Inc. The Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol CNSY, effective market open on the same day.
The new name reflects the Company's de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. The Company has expanded beyond targeted radiotherapeutics because effective solutions for CNS... More
